# TZIELD® (teplizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/teplizumab

> The FDA approved TZIELD® (teplizumab), sponsored by Sanofi (SNY), on Nov 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TZIELD® (teplizumab) |
| Codes | SAR446681 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Type 1 Diabetes Mellitus](https://sec-api.dev/indications/type-1-diabetes-mellitus) |
| Modality | antibody |
| FDA designations | accelerated, breakthrough, priority review |

## Timeline

### Nov 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-20, last confirmed 2025-03-20.
- SEC Form 10-K (accession 0001125345-25-000042): "In November 2022, the U.S. FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D, which triggered a $60.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1125345/000112534525000042/mgnx-20241231.htm
- SEC Form 10-K (accession 0001125345-25-000042): "The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022." https://www.sec.gov/Archives/edgar/data/1125345/000112534525000042/mgnx-20241231.htm

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Type 1 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06791291

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Type 1 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06791291

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 1 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07088068 (A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07088068

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 1 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07088068 (A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07088068

## Same indication

- [BMF-219](https://sec-api.dev/pdufa/bmf-219) (BMEA)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)
- [Technosphere insulin](https://sec-api.dev/pdufa/technosphere-insulin) (MNKD)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/teplizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TZIELD® (teplizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/teplizumab

```bibtex
@misc{secapidev_pdufa_teplizumab_20261116,
  title        = {TZIELD® (teplizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/teplizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_teplizumab_20261116","title":"TZIELD® (teplizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/teplizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
